Psilocybin Therapy Guide: A Complete Guide to Therapeutic Use

What Is Psilocybin and Why Are People Using It Therapeutically?

Psilocybin is a naturally occurring compound found in more than 200 species of mushrooms, often referred to as magic mushrooms. On its own it is largely inactive. Once ingested, the body converts it to psilocin, which is the molecule responsible for the changes in perception, mood, and thought that define the experience. What separates therapeutic use from recreational use is not the compound itself but the structure around it. In a therapeutic context, psilocybin is taken once or occasionally twice, in a prepared setting, with trained support before, during, and after the session.

Interest has grown because conventional treatments leave a significant number of people without relief. Many seekers arrive after years of antidepressants, talk therapy, or both, looking for something that addresses the underlying patterns rather than managing symptoms indefinitely. The research is genuinely promising in several areas, but it is also still maturing, and honest framing matters more here than enthusiasm.

How Does Psilocybin Work in the Brain?

Once psilocybin converts to psilocin, it activates specific serotonin receptors in the prefrontal cortex, the region most involved in mood, self-reflection, and how we interpret our own experience. What follows is a temporary window in which the brain becomes unusually flexible. Connections that normally stay fixed loosen, and regions that rarely communicate begin to exchange signals more freely. Researchers call this increased neuroplasticity, and it appears to be central to why the effects can outlast the experience itself.

This matters because it offers a plausible explanation for something that puzzles people new to the topic. A single guided session can produce changes that persist for weeks or months, which is very different from how a daily medication works. The current thinking is that the experience opens a period of heightened flexibility, and the preparation and integration around the session help a person make use of that window. The medicine creates the opening. The work done around it shapes what comes through.

What Forms Does Psilocybin Come In?

Outside of a clinical trial, psilocybin appears in several forms, and understanding them helps separate marketing from reality. The most common forms people encounter include:

• Dried whole mushrooms. The most familiar form, usually consumed directly. Potency varies considerably from one batch to the next, which is the central challenge of dosing without a known source.
• Tea. Mushrooms steeped in hot water, frequently with ginger to ease the nausea that some people experience. Many find the onset gentler and the stomach effects milder.
• Lemon tek. Dried mushrooms soaked in lemon or lime juice before ingestion. The acidity is thought to begin converting psilocybin to psilocin before it reaches the stomach, which can speed onset and intensify the experience.
• Capsules. Ground mushrooms in gelatin or vegan capsules, often used when people want more consistent dosing across sessions.
• Chocolates and edibles. Increasingly common, though dose consistency varies widely and is difficult to verify.
• Synthetic, pharmaceutical-grade psilocybin. Used in clinical trials and regulated programs, where each dose is measured precisely. This is the form behind most of the published research.

The clinical form is the most precise, but most people exploring this path are not in a clinical trial. Knowing the real-world forms is part of making an informed, safe decision rather than relying on assumptions.

How Is Psilocybin Dosed?

Dosing is where imprecision causes the most trouble, because milligrams of psilocybin mean very little to someone holding dried mushrooms. The two need to be paired. In the COMP360 Phase 2b trial, a single 25mg dose of synthetic psilocybin, roughly equivalent to 3 to 4 grams of dried Psilocybe cubensis, produced significant antidepressant effects in people with treatment-resistant depression. As a general reference, keeping in mind that potency varies significantly:

• Low or threshold dose: approximately 1 to 2 grams of dried Psilocybe cubensis, around 7 to 14mg psilocybin.
• Moderate dose: approximately 2 to 3.5 grams, around 14 to 25mg psilocybin.
• Full or high dose: approximately 3.5 to 5 grams, around 25 to 35mg psilocybin.
• Hero dose: anything north of 5 grams (typically 5-8 grams)

These ranges are approximate by necessity. Psilocybin content varies with strain, the specific specimen, and storage conditions, which is one reason weight-based dosing alone is unreliable without a known, measured source. Precision is one of the clearest advantages of a professionally supported, regulated setting.

Are All Mushrooms the Same? Understanding Strain Variety

They are not, and assuming they are is a common and avoidable mistake. Psilocybin mushrooms come in many varieties with meaningfully different potency. A few examples illustrate the range:

• Golden Teacher: moderate potency, widely available, often suggested for people new to the experience.
• Penis Envy: considerably higher psilocybin content than most strains, and not appropriate for beginners.
• B+: moderate potency with a relatively forgiving onset, popular in guided settings.
• Albino A+: moderate to high potency with a faster onset.
• Mazatapec: gentler in character, with a long history of traditional use in Mazatec ceremonies.

Because potency differs so much between strains, the same weight can produce very different experiences. This is a major reason that dosing by weight alone is imprecise, and why a known source and professional preparation matter.

What Does the Research on Psilocybin Therapy Actually Show?

The evidence is strongest for depression and anxiety. In a randomized trial conducted at Johns Hopkins and published in JAMA Psychiatry in 2021, 24 adults with major depressive disorder received psilocybin with psychological support, and most showed rapid and substantial reductions in depression symptoms, with benefits still present at follow-up. The COMP360 Phase 2b trial, the largest of its kind with 233 participants across 10 countries and published in the New England Journal of Medicine in 2022, found that a single 25mg dose produced a statistically significant drop in depression symptoms, with roughly 29 percent of participants in remission at three weeks.

These are meaningful results, and they should be read with their limits in view. The Johns Hopkins study was small and used a waiting-list comparison rather than an active placebo. The COMP360 trial was larger and more rigorous, but durability over many months was more modest than the early response, and Phase 3 work is still underway. The research is genuinely encouraging, particularly for people who have not responded to standard treatment, but it does not yet support claims of a cure. For a closer look at how psilocybin compares with the one widely legal alternative, our guide to psilocybin versus ketamine therapy walks through the trade-offs. Sustained outcomes are covered in our overview of what the research shows about long-term effects.

What Are the Risks and Who Should Be Cautious?

Psilocybin is not physically addictive and has a wide margin of physiological safety, but that does not make it appropriate for everyone. The most important cautions are psychological. A personal or family history of psychosis or bipolar disorder is a serious concern, because the experience can precipitate episodes in vulnerable individuals. Certain heart conditions and some medications, including lithium, raise additional flags. People taking SSRIs need to plan carefully, since these interact with how psilocybin works and require informed guidance rather than guesswork.

Beyond medical screening, the experience itself can be intensely challenging. Difficult moments are common and are not automatically harmful, but navigating them is precisely where preparation and skilled support make the difference. A full account of who should pause before proceeding is covered in our guide to psychedelic therapy contraindications, and the conversation to have with your physician is laid out in our guide to talking to your doctor about psychedelic therapy.

Why Does Professional Support Matter So Much?

The variable that most consistently shapes outcomes is not the dose. It is the quality of preparation, the setting, and the integration that follows. The published trials that produced strong results all paired psilocybin with structured psychological support across preparation, the session itself, and the weeks afterward. Stripping that support away does not simply reduce the benefit. It changes the nature of the experience and raises the risk.

This is where a concierge approach is built to help. JourneyŌM matches seekers with vetted professional guides and supports them through the full arc rather than a single session, which is the structure the evidence points to. For more on why the match between guide and seeker matters as much as the medicine, see our guide to choosing a psychedelic guide.